Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1143 plus Avelumab in advanced solid tumors and NSCLC
NCT03270176Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Oct 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of xevinapant in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Debiopharm. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate up to 2 years. Started Oct 2017; status: completed.
02
Drugs
xevinapant
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03270176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270176.